Background

Radiotherapy is one of the most common and effective treatment methods for cancer, and improving the radiosensitivity of tumor tissues during the treatment process is vital. We report the mechanisms of glycogen synthase kinase 3 (GSK-3) β-regulated autophagy and the effects of autophagy on radiosensitivity in non-small cell lung cancer (NSCLC).

Method

Immunohistochemical staining was performed to determine GSK-3β tissue expression in 89 NSCLC patients with follow-up data and the expression status of GSK-3β and autophagy in NSCLC tissues after X-ray radiotherapy. Western blots were used to quantitate changes in autophagy-related protein expression after A549 cells were treated with GSK-3β inhibitors and after H460 cells were transfected with GSK-3β mutants with different activities and X-ray irradiated. Clonogenic assays were used to measure the effect of autophagy on cellular proliferation.

Glycogen synthase kinase 3 (GSK-3) β is a serine/threonine protein kinase, and its activity is regulated by the phosphorylation of specific sites. Tyr216 phosphorylation can enhance kinase activity, whereas Ser9 phosphorylation can inhibit kinase activity [1]. Recently, some studies have indicated that GSK-3β can regulate autophagy; however, others suggest that the regulatory effects of GSK-3β are not the same in different cancers [2–7].

Autophagy is a lysosome degradation process that plays a dynamic regulatory role in tumor occurrence [8]. Recent studies have shown that the autophagy status of cells affects the radiosensitivity of tumors [9]. In addition, these responses vary in different types of cells. Studies have shown that inhibiting autophagy in hepatocellular carcinoma, pancreatic cancer, prostate cancer, ovarian carcinoma, throat squamous cell carcinoma, and malignant gliomas can enhance radiosensitivity [10–15]. However, other studies show different results [16, 17], and the specific mechanisms associated with this process remain unclear.

Radiotherapy is one of the most common and effective treatment methods for cancer, and radioresistance due to hypoxia or drug resistance has marked effects on therapeutic efficacy [18]. Thus, improving the radiosensitivity of tumor tissues during the treatment process is vital [19]. Compared to small cell lung cancer, non-small cell lung cancer (NSCLC) accounts for the majority of lung cancer cases, and this malignancy is inherently radioresistant. Thus, investigating methods for increasing the radiosensitivity of NSCLC will be beneficial for targeted therapy regimens. As mentioned above, the role of GSK-3β in cancer, particularly NSCLC and radiosensitivity, is unclear.

In our study, we investigated the regulatory mechanisms of GSK-3β in autophagy and the effects of GSK-3β-regulated autophagy on radiosensitivity. We found that GSK-3β inhibits autophagy. When GSK-3β levels increased, autophagy levels decreased, and NSCLC radiosensitivity was enhanced. Consequently, the activation of kinases through phosphorylation plays an important role in GSK-3β-mediated autophagy inhibition.

2.1 Patients and specimens

We collected 89 tumor specimens from patients (67 males and 22 females) who underwent surgery at the First Affiliated Hospital of China Medical University between 2000 and 2004. All patients were diagnosed with squamous cell carcinoma, adenocarcinoma, or large cell carcinoma. In addition, all patients underwent curative surgical resection without prior chemotherapy or radiation therapy, and complete follow-up data were available.

According to the 2015 World Health Organization (WHO) classification of lung cancer, the samples included 45 squamous cell carcinomas, 41 adenocarcinomas, and three large cell carcinomas. A total of 16 tumors were well-differentiated, whereas 41 and 32 were moderately and poorly differentiated, respectively. Tumor staging was performed according to the TNM classification of the International Union Against Cancer (UICC). Sixty cases were pathological stage I or II, and 29 cases were stage III. The median age of the patients was 59 years (range: 33–76 years). This study was approved by the Institutional Review Board of China Medical University.

2.3 Immunohistochemistry

After irradiation with 2-Gy X-rays, samples were fixed in 10% neutral formalin, embedded in paraffin, and cut into 4-μm thick sections. Immunostaining was performed using the streptavidin-peroxidase method. The sections were incubated with GSK-3β (1:200, Santa Cruz, CA, USA), p-GSK-3βSer9 (1:200, Bioss, China), p-GSK-3βTyr216 (1:200, Bioss, China), LC3 (1:200, Wanleibio, China), AMPK (1:200, Wanleibio, China), and p62 (1:200, Wanleibio, China) primary antibodies at 4 °C overnight, followed by incubation with a biotinylated goat anti-rabbit IgG secondary antibody. The sections were incubated with horseradish peroxidase-conjugated streptavidin-biotin (Ultrasensitive; MaiXin, China), and diaminobenzidine (MaiXin) was used for coloration. Counterstaining was performed with Harris’s hematoxylin. The sections were dehydrated in graded concentrations of alcohol before mounting. The staining intensities were scored as 0 (no signal), 1 (weak), 2 (moderate), or 3 (high). Staining percentages were scored as 1 (1–25%), 2 (26–50%), 3 (51–75%), or 4 (76–100%). The scores of each tumor sample were multiplied to yield a final score of 0–12. Tumors with a score ≥ 3 were considered to be positive for GSK-3β expression. Tumor samples with scores between 1 and 2 were categorized as showing weak expression, whereas those with scores of 0 were defined as negative for GSK-3β expression.

2.7 Colony formation assay

H460 cells were transfected with GSK-3β-WT, GSK-3β-S9A, GSK-3β-K85R, or negative control plasmids for 48 h. A549 cells were treated with the GSK-3 inhibitor SB216763 (Cell Signaling Technology, Danvers, MA, USA) for 24 h, and H460 cells were treated with rapamycin (KeyGEN Biotech, Nanjing, China) and 3-methyladenine (3-MA, KeyGEN Biotech) for 24 h. Cells were then irradiated with 2-Gy X-rays, transferred to three 6-cm cell culture dishes (1000 cells per dish) and incubated for 2 weeks. Then, the plates were washed with PBS and stained with Giemsa solution. Colonies with more than 50 cells were counted under a microscope. All experiments were performed in triplicate.

2.8 Statistical analysis

SPSS 22.0 (SPSS, Chicago, IL, USA) was used for all analyses. A chi-square test was used to examine possible correlations between GSK-3β expression and clinicopathological factors. Kaplan-Meier survival analyses were performed for all 89 cases and compared using the log-rank test. Image data from the Western blots were compared by using the Mann-Whitney U test, and P < 0.05 was considered to indicate a statistically significant difference.

GSK-3β, p-GSK-3βSer9, and p-GSK-3βTyr216 expression in NSCLC tissues after X-ray irradiation. a, e, i, and M are the moderately differentiated adenocarcinoma tissues without X-ray irradiation, and b, f, j, and n are the tumor tissues that received 2-Gy X-ray irradiation. a and b are stained with HE (200×); e and f have immunohistochemical staining for GSK-3β; i and j have immunohistochemical staining for GSK-3βSer9; and m and n have immunohistochemical staining for GSK-3βTyr216. As shown in the figure, after 2-Gy X-ray irradiation of the adenocarcinoma samples, GSK-3β expression did not change significantly, but GSK-3βSer9 and GSK-3βTyr216 expression was significantly upregulated. c, g, k, and o are the poorly differentiated squamous cell carcinoma tissues without X-ray irradiation, and d, h, l, and p are the tumor tissues that received 2-Gy X-ray irradiation. c and d are stained with HE (200×); g and h have immunohistochemical staining for GSK-3β; k and l have immunohistochemical staining for GSK-3βSer9; and o and p have immunohistochemical staining for GSK-3βTyr216. As shown in the figure, after 2-Gy X-ray irradiation of the adenocarcinoma samples, GSK-3β and GSK-3βSer9 expression was downregulated, whereas GSK-3βTyr216 expression did not change significantly

LC3, P62 and AMPK expression in NSCLC tissues after X-ray irradiation. After 2-Gy X-ray irradiation of the adenocarcinoma samples (moderately differentiated, a and b are stained with HE, 200×), LC3 expression was significantly upregulated (e is the control, and f indicates LC3 upregulation in the adenocarcinoma samples after X-ray irradiation); p62 expression was downregulated (i is the control, and j indicates p62 downregulation in the adenocarcinoma samples after X-ray irradiation); and AMPK expression was upregulated (m is the control, and n indicates AMPK upregulation in the adenocarcinoma samples after X-ray irradiation). After 2-Gy X-ray irradiation of the squamous cell carcinoma samples (poorly differentiated, c and d are stained with HE, 200×), LC3 expression was significantly upregulated (g is the control, and h indicates LC3 upregulation in the squamous cell carcinoma samples after X-ray irradiation); p62 expression was downregulated (k is the control, and l indicates p62 downregulation in the squamous cell carcinoma samples after X-ray irradiation); and AMPK expression was slightly upregulated (o is the control, and p indicates slight AMPK upregulation in the squamous cell carcinoma samples after X-ray irradiation)

3.4 Effects of GSK-3β on X-ray-induced changes in autophagy

To show that GSK-3β can affect the X-ray-induced expression of autophagy markers, we utilized H460 cells, which express GSK-3β, for transfection, and we inhibited GSK-3β in A549 cells. The treated cells were irradiated with 2-Gy X-rays. The results showed that after transfection with GSK-3β-WT and constitutively active GSK-3β-S9A, LC3 protein expression levels were decreased, and autophagy was inhibited. Transfection with the catalytically inactive GSK-3β-K85R plasmid did not significantly change autophagy levels (Fig. 4). Conversely, GSK-3β inhibition increased AMPK and LC3 protein expression levels, and these changes are indicative of autophagy. After X-ray irradiation only, GSK-3β and p62 protein levels decreased, and LC3 protein levels increased; these findings suggest that autophagy was promoted (Fig. 5). After GSK-3β transfection and X-ray irradiation, AMPK and LC3 protein expression levels decreased, and p62 protein expression levels increased. Of the GSK-3β mutants, GSK-3β-S9A yielded greater effects than GSK-3β-WT and the catalytically inactive GSK-3β-K85R. Conversely, GSK-3β inhibition followed by X-ray irradiation upregulated AMPK and LC3 protein expression, suggesting that autophagy was promoted.

Fig. 4

GSK-3β inhibited cellular autophagy. Western blotting showed that (a) after X-ray irradiation alone, GSK-3β and p62 levels decreased, whereas AMPK and LC3 levels did not change significantly in H460 cells. After transfection with GSK-3β with different activity levels, p62, AMPK, and LC3 levels decreased. After transfection with GSK-3β with different activity levels and X-ray irradiation, p62 levels increased, whereas AMPK and LC3 levels decreased. These changes were more significant for transfection with the active GSK-3β-S9A mutant than for transfection with the GSK-3β-WT or inactivated GSK-3β-K85R mutant (b, c, d). *P < 0.05

3.5 Effects of autophagy on X-ray-induced cell growth

To examine the effects of autophagy on X-ray-induced cell growth, we determined the clonogenic ability of cells after treatment and X-ray irradiation. The results showed that after transfection with GSK-3β-S9A, clonogenic ability and cell survival were decreased. After GSK-3β inhibition, clonogenic ability and cell survival increased. We also used 3-MA to inhibit autophagy and rapamycin to increase autophagy. The results showed that upon X-ray induction, inhibiting autophagy decreased clonogenic ability and cell survival (Fig. 6).

Fig. 6

Clonogenic ability of cells after treatment and X-ray irradiation. Colony formation in H460 cells transfected with GSK-3β with different activity levels [wild type GSK-3β (GSK-3β-WT), constitutively active GSK-3β-S9A, and catalytically inactive GSK-3β-K85R)] and X-ray irradiation (a). After transfection with GSK-3β with different activity levels, the clone-forming ability of activated GSK-3β-S9A was reduced, and cell viability was decreased. Colony formation in A549 cells after GSK-3β inhibition (SB216763) and X-ray irradiation (b). After inhibiting GSK-3β activity, the clone-forming ability and cell viability increased. Colony formation in H460 cells after inhibiting or promoting autophagy (cells were treated with the autophagy inducer rapamycin and the autophagy inhibitor 3-MA) and X-ray irradiation (c). After inhibiting autophagy with 3-MA, the reduction in clone-forming ability was more significant, and cell viability was decreased

Our experimental results showed that GSK-3β is intimately associated with the degree of differentiation in NSCLC but is not correlated with tumor TNM staging or lymph node metastasis. Patients with negative GSK-3β expression had a better prognosis than those with positive GSK-3β expression. GSK-3β can be expressed as wild type, constitutively active, and catalytically inactive forms. All of these GSK-3β forms were assessed in the clinical samples. Consequently, our results might have been due to the inability of the GSK-3β antibodies used in our study to distinguish between the constitutively active and catalytically inactive forms of GSK-3β. X-ray irradiation resulted in the downregulation of GSK-3β and the upregulation of p-GSK-3βSer9 and p-GSK-3βTyr216 in NSCLC tissues. GSK-3β is a type of serine/threonine protein kinase, and its activity is regulated by the phosphorylation of specific sites. Tyr216 phosphorylation can increase kinase activity, whereas Ser9 phosphorylation can inhibit kinase activity [1]. Therefore, we hypothesized that GSK-3β activity is associated with radiosensitivity in NSCLC tissue and that kinase activation through phosphorylation plays an important role. Previous studies have shown that X-ray irradiation can change the activation status of GSK-3β to regulate tissue radiosensitivity, but the specific effector mechanisms remain unclear [21, 22]. One study has found that the radioresistance was lower in human non-small cell lung cancer (NSCLC) cell lines when the miR-21 level is lower. GSK-3β regulated radiosensitivity through miR-21, high miR-21 levels has a negative correlation with low GSK-3β levels in different human tumors (pheochromocytoma/paraganglioma, kidney tumor and testicular germ cell tumors) [23]. We think the differential results in these studies might be due to the different cell lines and the specific pathway to radioresistance was also different. In the next study, we will increase the NSCLC cell lines and the number of NSCLC specimens.

Our study showed that X-ray irradiation can increase autophagy levels in NSCLC tissues. Cancer cells are thought to survive due to autophagy, and this effect presents as radioresistance [24, 25]. However, autophagy can have opposing effects on cell survival. In different stages of tumor growth, autophagy plays completely different roles. In the early phases of tumor growth, inhibiting autophagy can increase anabolism and cancer cell proliferation and decrease protein degradation. At this early stage, autophagy plays a tumor suppressive role. As the tumor progresses, and particularly when there is an insufficient number of blood vessels to supply nutrients to the tumor, tumor cells can overcome nutrient deprivation and hypoxia and survive by upregulating autophagy. This process can also remove mitochondria from cells to protect cells from radiation damage and support continuous tumor proliferation. In different types of tumors, the functions of autophagy are also different. Some studies have found that autophagy can inhibit tumor cell proliferation [26–29]. However, other studies have found that this process can increase tumor cell death [30–38]. Studies have shown that the autophagy status of cells can affect radiosensitivity in tumors [9]. Our study shows that X-rays induce changes in GSK-3β, p-GSK-3βSer9, and p-GSK-3βTyr216 levels in NSCLC tissues, and we hypothesized that GSK-3β may regulate autophagy in NSCLC to alter radiosensitivity.

We also showed that GSK-3β can affect X-ray-induced autophagy, as increased GSK-3β expression inhibited autophagy, and this effect was more significant with the constitutively active variant. In addition, GSK-3β inhibition resulted in increased autophagy. Similar studies on skin squamous cell carcinoma [2], breast carcinoma [3], prostate adenocarcinoma [4], and pancreatic carcinoma [5] all support this result. However, some studies have demonstrated results completely opposite to those of our study regarding how GSK-3β phosphorylation affects autophagy [6, 7]. These differences might be due to the type of cancer studied and the nutritional status of the cells. The exact mechanisms associated with these differences require further investigation. The specific pathway through which GSK-3β regulates autophagy also requires further examination.

Additionally, we examined the effects of GSK-3β-regulated autophagy on radiosensitivity. We found that GSK-3β inhibited cell proliferation, and this effect was more pronounced with the constitutively active variant. Inhibiting autophagy also inhibited cell proliferation, which could lead to increased radiosensitivity. The results of previous studies that used different types of tumors, including hepatocellular carcinoma [10], pancreatic cancer [11], prostate cancer [12], ovarian carcinoma [13], throat squamous cell carcinoma [14], and malignant gliomas [15], also support our findings. However, in breast adenocarcinoma, promoting autophagy can increase radiosensitivity [16]. This result might be due to vitamin D3 activity in breast adenocarcinoma [17]. The differential results reported in these studies might be due to the type of tumor and other related factors. Thus, the specific associated mechanisms remain unclear.

In summary, our study showed that GSK-3β can inhibit autophagy in NSCLC and that phosphorylation levels and sites play crucial roles in this process. Moreover, GSK-3β inhibited autophagy to increase radiosensitivity in NSCLC. These results provide new insight into NSCLC radiosensitivity and corresponding clinical treatments.

Funding

This work was supported by the Liaoning Nature Science Foundation (grant No. 2015020491 to Yang Han) and the National Nature Science Foundation of China (grant No. 81000995 to Yang Han).

Availability of data and materials

The raw data are available upon request to the following e-mail address: 18900911058@189.cn

Authors’ contributions

JR and YH conceived and designed the study. JR and QW collected the data and participated in the data analysis and mortality follow-ups. JR and LJ analyzed the data and prepared the figures for verification. YC and GL reviewed the slides. TL and YH interpreted the results, critically revised the manuscript for important intellectual content and approved the final version of the manuscript. All authors have read and approved the final manuscript.

Ethics approval and consent to participate

This study was approved by the Institutional Review Board of China Medical University (No. 2015000226). Additional patient consent for this retrospective study was not required.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.